Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Key Points

• Earnings miss: Eton reported $0.05 EPS for the quarter versus a $0.12 consensus, although revenue of $21.3 million modestly beat estimates.
• Strong product momentum and guidance: Q4 product revenue rose 83% YoY, management reiterated the DESMODA launch with $30M–$50M peak sales potential and is guiding 2026 revenue >$110M with adjusted EBITDA ≥30%.
• Near‑term cash and expense risk: Q4 included an $11.6M operating cash outflow leaving $25.9M on hand, and FDA fees plus the HEMANGEOL relaunch are expected to add about $6.3M of incremental SG&A in 2026.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.07), Zacks reports. Eton Pharmaceuticals had a negative return on equity of 11.32% and a negative net margin of 9.50%.The business had revenue of $21.28 million during the quarter, compared to the consensus estimate of $20.58 million.

Here are the key takeaways from Eton Pharmaceuticals' conference call:

• 2025 revenue and profitability accelerated materially—Q4 product revenue was $21.3M (up 83% YoY), adjusted EBITDA margin improved to 29%, and management guides 2026 revenue >$110M with adjusted EBITDA ≥30%.
• DESMODA launch — the FDA‑approved oral liquid desmopressin (no age restriction) launched quickly and has shown early traction; management reiterates $30M–$50M peak sales guidance and estimates ~ $80k net revenue per patient per year.
• HEMANGEOL acquisition ($14M cash) will be relaunched May 1 with a shift to Eton’s rare‑disease distribution model, a zero copay program, and seven dedicated hires, which management expects to materially improve margins and make it a top product by 2027.
• Near‑term cash and SG&A pressure — Q4 included a $11.6M operating cash outflow driven by Medicaid rebates and $3.5M in FDA program fees, leaving $25.9M cash on hand, while FDA fees and HEMANGEOL are expected to add roughly $6.3M of incremental SG&A in 2026.
• Pipeline and label expansion milestones progressing—Increlex protocol submitted (first patient targeted in Q3), KHINDIVI bioequivalence study dosed (supplement expected in Q3 with potential mid‑2027 launch), and an ET‑700 PET study begins in April; these could be meaningful upside but carry execution and timing risk.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON opened at $20.77 on Friday. The company has a market capitalization of $557.05 million, a P/E ratio of -83.08 and a beta of 1.19. Eton Pharmaceuticals has a 1-year low of $11.09 and a 1-year high of $23.00. The firm's 50 day simple moving average is $16.59 and its two-hundred day simple moving average is $17.34. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.63 and a quick ratio of 1.25.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP bought a new position in Eton Pharmaceuticals in the 3rd quarter worth $37,000. Legal & General Group Plc purchased a new stake in Eton Pharmaceuticals in the 2nd quarter worth $41,000. Caitong International Asset Management Co. Ltd bought a new stake in Eton Pharmaceuticals during the fourth quarter valued at about $44,000. New York State Common Retirement Fund bought a new stake in Eton Pharmaceuticals during the second quarter valued at about $115,000. Finally, State of Wyoming lifted its position in shares of Eton Pharmaceuticals by 50.0% in the fourth quarter. State of Wyoming now owns 8,161 shares of the company's stock valued at $138,000 after acquiring an additional 2,721 shares in the last quarter. 27.86% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ETON. HC Wainwright lifted their price target on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Zacks Research upgraded shares of Eton Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Thursday, January 1st. Wall Street Zen cut shares of Eton Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $31.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.